Welcure Drugs & Pharmaceuticals Ltd (WELCURE) — shareholding pattern, promoter holding, financials and share price
About Welcure Drugs & Pharmaceuticals Ltd (WELCURE)
Welcure Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as WELCURE and on the BSE under scrip code 524661. Its ISIN is INE331C01025.
Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare. [1]
Welcure Drugs And Pharmaceuticals (WDPL) is engaged in the manufacture of bulk drugs and pharmaceutical formulations, including antibiotics and vitamins, offering over a hundred varieties of products.
The company has a strategic collaboration agreement with a Russian firm to be the sole selling agent for Stevioside, a sugar substitute, enhancing its portfolio and market reach.
Listed peers in Pharmaceuticals: Parmax Pharma Ltd, Medi Caps Ltd, Walpar Nutritions Ltd, Sunrest Lifescience Ltd, Chandra Bhagat Pharma Ltd, Medicamen Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹0.26 a share on 10 Jul 2026, Welcure Drugs & Pharmaceuticals Ltd (WELCURE) was valued at a price-to-earnings ratio of -1.82x against an industry P/E of 36.41x and a price-to-book of 0.31x on a book value of ₹0.83 per share as of Mar 2025. Solomo computes return on equity of -16.57% and return on capital employed of -2.63% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -1.82x
- Industry P/E
- 36.41x
- P/B
- 0.31x
- EPS (TTM)
- ₹-0.14
- Book value / share
- ₹0.83
- ROE
- -16.57%
- ROCE
- -2.63%
- ROA
- -6.36%
- Debt / equity
- 1.2x
- Dividend yield
- 0%
- EBITDA margin
- -1.62%
- 52-week range
- ₹0.23 – ₹1.18
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2008In the year ended Mar 2008, Welcure Drugs & Pharmaceuticals Ltd (WELCURE) reported revenue of ₹25.67 crore, net profit of ₹-1.93 crore and earnings per share of ₹-0.13. That compares with revenue of ₹24.67 crore and net profit of ₹-0.86 crore in Mar 2007. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, net profit ₹-50 crore (standalone).
| Metric | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Revenue (₹ cr) | 16.36 | 24.67 | 25.67 |
| Net profit (₹ cr) | -1.89 | -0.86 | -1.93 |
| EPS (₹) | -0.13 | -0.06 | -0.13 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 84.35% | 212.41% | 516.06% | 4.05% |
| Profit growth | 43.25% | - | 351.49% | -124.42% |
| Stock price CAGR | 6% | -11% | -11% | -77% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 0% of Welcure Drugs & Pharmaceuticals Ltd (WELCURE) (unchanged from the previous quarter). Market capitalisation was ₹32 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 0% | - | - | - | 100% |
| Dec 2025 | 0% | - | 0% | 0% | 100% |
| Sep 2025 | 0% | - | - | - | 100% |
| Jun 2025 | 0% | - | - | - | 100% |
| Mar 2025 | 0% | - | - | - | 100% |
| Dec 2024 | 0% | - | - | - | 100% |
| Sep 2024 | 0% | - | - | - | 100% |
| Jun 2024 | 0% | - | - | - | 100% |